HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PF-04523655

targets the RTP801 gene; for treating neovascular age-related macular degeneration

Networked: 7 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleic Acids: 11752
  - RNA: 69704
    - Untranslated RNA: 2850
      - Small Untranslated RNA: 566
        Small Interfering RNA: 25779
        PF-04523655: 7
    - Antisense RNA: 1599
      - Small Interfering RNA: 25779
        PF-04523655: 7
- Antisense Elements (Genetics): 31
  - Antisense RNA: 1599
    - Small Interfering RNA: 25779
      - PF-04523655: 7

Experts

1.	Basile, Anthony S: 2 articles (03/2014 - 11/2012)
2.	Aitchison, Roger: 2 articles (11/2012 - 09/2012)
3.	Chi-Burris, Katherine: 2 articles (11/2012 - 09/2012)
4.	Erlich, Shai S: 2 articles (11/2012 - 09/2012)
5.	Klamerus, Karen J: 2 articles (11/2012 - 09/2012)
6.	Nduaka, Chudy I: 2 articles (11/2012 - 09/2012)
7.	Nguyen, Quan Dong: 2 articles (11/2012 - 09/2012)
8.	Paggiarino, Dario A: 2 articles (11/2012 - 09/2012)
9.	Rosenblatt, Irit: 2 articles (11/2012 - 09/2012)
10.	Schachar, Ronald A: 2 articles (11/2012 - 09/2012)

Related Diseases

1.	Macular Edema 01/01/2019 - "PF-04523655, a 19-nucleotide methylated double-stranded siRNA targeting the RTP80 gene, showed a dose-related improvement in best-corrected visual acuity (BCVA) in patients affected by diabetic macular edema. " 11/15/2012 - "Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study)." 11/15/2012 - "To evaluate the safety and efficacy of three doses of PF-04523655, a 19-nucleotide methylated double stranded siRNA targeting the RTP801 gene, for the treatment of diabetic macular edema (DME) compared to focal/grid laser photocoagulation. "
2.	Macular Degeneration (Age-Related Maculopathy) 09/01/2012 - "To evaluate the efficacy of different dosing paradigms of PF-04523655 (PF) versus ranibizumab (comparator) in subjects with neovascular age-related macular degeneration (AMD). " 08/01/2012 - "To evaluate the safety, tolerability, pharmacokinetics, and dose-limiting toxicities of a single intravitreal (IVT) injection of PF-04523655, a 19-nucleotide, O-methyl stabilized, double-stranded small interfering ribonucleic acid targeting the RTP801 gene in patients with neovascular age-related macular degeneration (AMD). " 09/01/2012 - "Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study)." 01/01/2021 - "This review provides a detailed insight into the recent developments and clinical trials that have been conducted for several gene-silencing therapies, including ISTH0036, SYL040012, SYL1001, PF-04523655, Sirna-027, QR-110, QR-1123, QR-421a and IONIS-FB-LRX in glaucoma, dry eye disease, age-related macular degeneration, diabetic macular oedema and various inherited retinal diseases. "
3.	Glaucoma 02/01/2021 - "RNA interference (RNAi) is being increasingly used in the treatment of these disorders with siRNA drugs, bevasiranib, AGN211745 and PF-04523655 for AMD, and SYL040012 and QPI-1007 for glaucoma. " 01/01/2021 - "This review provides a detailed insight into the recent developments and clinical trials that have been conducted for several gene-silencing therapies, including ISTH0036, SYL040012, SYL1001, PF-04523655, Sirna-027, QR-110, QR-1123, QR-421a and IONIS-FB-LRX in glaucoma, dry eye disease, age-related macular degeneration, diabetic macular oedema and various inherited retinal diseases. "
4.	Dry Eye Syndromes (Dry Eye Syndrome) 01/01/2021 - "This review provides a detailed insight into the recent developments and clinical trials that have been conducted for several gene-silencing therapies, including ISTH0036, SYL040012, SYL1001, PF-04523655, Sirna-027, QR-110, QR-1123, QR-421a and IONIS-FB-LRX in glaucoma, dry eye disease, age-related macular degeneration, diabetic macular oedema and various inherited retinal diseases. "
5.	Retinal Diseases 01/01/2021 - "This review provides a detailed insight into the recent developments and clinical trials that have been conducted for several gene-silencing therapies, including ISTH0036, SYL040012, SYL1001, PF-04523655, Sirna-027, QR-110, QR-1123, QR-421a and IONIS-FB-LRX in glaucoma, dry eye disease, age-related macular degeneration, diabetic macular oedema and various inherited retinal diseases. "

Related Drugs and Biologics

1.	Small Interfering RNA (siRNA)
2.	Ranibizumab (Lucentis)
3.	ISTH0036
4.	RNA (Ribonucleic Acid)
5.	bevasiranib

Related Therapies and Procedures

1.	Light Coagulation
2.	Lasers (Laser)
3.	Therapeutics